Zevra Therapeutics Appoints New CFO to Drive Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Source: NASDAQ.COM
Zevra Therapeutics' stock surged by 21.27% as it crossed above the 5-day SMA, reflecting strong investor interest following the announcement of Justin Renz as the new CFO.
The appointment of Justin Renz, who brings over 25 years of financial leadership experience in the biopharmaceutical industry, is expected to enhance Zevra's strategic plan and market position in rare diseases. His previous roles included significant contributions to the launch and commercialization of innovative medicines, which will support Zevra's financial foundation and growth trajectory.
This leadership change is likely to instill confidence among investors, as Renz's extensive experience in capital markets and strategic transactions positions Zevra for future success in the competitive rare disease market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZVRA
Wall Street analysts forecast ZVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.610
Low
21.00
Averages
24.00
High
26.00
Current: 12.610
Low
21.00
Averages
24.00
High
26.00
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Therapeutics Price Target Raised to $25 Amid Positive Analyst Sentiment
- Analyst Price Target Increase: Citizens raised Zevra Therapeutics' price target from $18 to $25 while maintaining an 'Outperform' rating, reflecting optimism regarding the extended market exclusivity of Miplyffa, which is expected to further boost investor confidence.
- Strong Market Performance: Shares of Zevra Therapeutics jumped 8% on Tuesday, reaching their highest level in nearly five years, as investors reacted strongly to favorable analyst commentary linked to recent patent developments, indicating enhanced market confidence in the company's long-term prospects.
- Miplyffa Sales Surge: In 2025, Miplyffa generated $87.4 million in revenue, accounting for over 80% of Zevra's total sales, marking a significant increase from $10.1 million the previous year, underscoring the drug's importance and market demand in treating rare neurological disorders.
- Investor Sentiment Shift: Retail sentiment surrounding ZVRA on Stocktwits shifted from 'neutral' to 'extremely bullish,' with message volumes surging nearly 1,200% over the past 24 hours, reflecting strong optimism about the stock's future performance.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Zevra's Patent Protection Extended to 2041 for MIPLYFFA
- Enhanced Patent Protection: Zevra Therapeutics announced that the new patent for its only FDA-approved drug, MIPLYFFA, will protect its market position until 2041, blocking cheaper generic alternatives and significantly boosting investor confidence while ensuring stable future cash flows.
- Significant Revenue Growth: In 2025, MIPLYFFA generated $87.4 million in net revenue, a substantial increase from $10.1 million in 2024, accounting for 82% of the company's total net revenue, indicating that the drug's strong market performance has propelled Zevra from a net loss to profitability.
- Analyst Outlook Positive: Cantor Fitzgerald analyst Kristen Kluska raised Zevra's price target from $24 to $34 while maintaining an 'Overweight' rating, citing the new patent's
See More
Zevra Submits MIPLYFFA Patent for Orange Book Listing
- Enhanced Patent Protection: Zevra Therapeutics has submitted a patent application for MIPLYFFA® (arimoclomol) with a validity extending to 2041, further strengthening its intellectual property protection and ensuring competitive advantage in the future market.
- Addressing Unmet Needs: MIPLYFFA represents a crucial therapeutic option for patients with Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease, highlighting the company's commitment to addressing patient needs.
- Market Access Strategy: By listing the patent in the FDA's Orange Book, Zevra aims to clarify the market exclusivity of its branded drug, thereby delaying the entry of generic competitors, protecting its market share, and enhancing long-term value.
- Patent Term Extension Application: The company has also applied for an extension of another patent set to expire in 2029, currently awaiting a determination from the U.S. Patent and Trademark Office, demonstrating its proactive strategy in intellectual property management.
See More
Zevra Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: Zevra Therapeutics has granted options to purchase a total of 33,000 shares of common stock to four new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in rare disease therapeutics.
- Award Plan Details: Under the 2023 Employment Inducement Award Plan, each inducement award vests over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal annual installments, ensuring employee retention on each vesting date.
- Strategic Positioning: Zevra focuses on broadening market access through geographic expansion and advancing key milestones, with its lead product already marketed in the U.S. for Niemann-Pick disease type C, demonstrating a strong foundation in rare disease treatment.
- Commitment to Long-Term Value: The company's vision is realized through disciplined execution of its strategic plan, emphasizing core values such as patient centricity, integrity, accountability, innovation, and courage, which drive the creation of long-term value.
See More
Zevra Therapeutics Reports Q1 2026 Earnings with Strong Growth Indicators
- Significant Revenue Growth: Zevra Therapeutics reported net revenue of $36.2 million in Q1 2026, with $24.6 million from MIPLYFFA sales in the U.S., indicating strong performance in the rare disease market and potential for increased market share moving forward.
- Asset Optimization and Debt Clearance: The company divested its SDX portfolio to Commave Therapeutics for $50 million and successfully retired its debt early, marking Zevra as debt-free, which enhances financial flexibility for future strategic investments.
- Expanded Patient Access Program: As of Q1 2026, Zevra's global Expanded Access Program (EAP) has enrolled 122 patients, up from 113 at the end of 2025, indicating positive progress in improving patient treatment accessibility.
- Diversified Clinical Development Pathways: Zevra is actively preparing for follow-up meetings with the FDA to accelerate clinical development and plans to boost MIPLYFFA enrollment through multiple pathways, demonstrating the company's responsiveness to market demands and adaptability.
See More
Zevra Therapeutics Price Target Raised to $25 Amid Positive Analyst Sentiment
- Analyst Price Target Increase: Citizens raised Zevra Therapeutics' price target from $18 to $25 while maintaining an 'Outperform' rating, reflecting optimism regarding the extended market exclusivity of Miplyffa, which is expected to further boost investor confidence.
- Strong Market Performance: Shares of Zevra Therapeutics jumped 8% on Tuesday, reaching their highest level in nearly five years, as investors reacted strongly to favorable analyst commentary linked to recent patent developments, indicating enhanced market confidence in the company's long-term prospects.
- Miplyffa Sales Surge: In 2025, Miplyffa generated $87.4 million in revenue, accounting for over 80% of Zevra's total sales, marking a significant increase from $10.1 million the previous year, underscoring the drug's importance and market demand in treating rare neurological disorders.
- Investor Sentiment Shift: Retail sentiment surrounding ZVRA on Stocktwits shifted from 'neutral' to 'extremely bullish,' with message volumes surging nearly 1,200% over the past 24 hours, reflecting strong optimism about the stock's future performance.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Zevra's Patent Protection Extended to 2041 for MIPLYFFA
- Enhanced Patent Protection: Zevra Therapeutics announced that the new patent for its only FDA-approved drug, MIPLYFFA, will protect its market position until 2041, blocking cheaper generic alternatives and significantly boosting investor confidence while ensuring stable future cash flows.
- Significant Revenue Growth: In 2025, MIPLYFFA generated $87.4 million in net revenue, a substantial increase from $10.1 million in 2024, accounting for 82% of the company's total net revenue, indicating that the drug's strong market performance has propelled Zevra from a net loss to profitability.
- Analyst Outlook Positive: Cantor Fitzgerald analyst Kristen Kluska raised Zevra's price target from $24 to $34 while maintaining an 'Overweight' rating, citing the new patent's
See More
Zevra Submits MIPLYFFA Patent for Orange Book Listing
- Enhanced Patent Protection: Zevra Therapeutics has submitted a patent application for MIPLYFFA® (arimoclomol) with a validity extending to 2041, further strengthening its intellectual property protection and ensuring competitive advantage in the future market.
- Addressing Unmet Needs: MIPLYFFA represents a crucial therapeutic option for patients with Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease, highlighting the company's commitment to addressing patient needs.
- Market Access Strategy: By listing the patent in the FDA's Orange Book, Zevra aims to clarify the market exclusivity of its branded drug, thereby delaying the entry of generic competitors, protecting its market share, and enhancing long-term value.
- Patent Term Extension Application: The company has also applied for an extension of another patent set to expire in 2029, currently awaiting a determination from the U.S. Patent and Trademark Office, demonstrating its proactive strategy in intellectual property management.
See More
Zevra Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: Zevra Therapeutics has granted options to purchase a total of 33,000 shares of common stock to four new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in rare disease therapeutics.
- Award Plan Details: Under the 2023 Employment Inducement Award Plan, each inducement award vests over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal annual installments, ensuring employee retention on each vesting date.
- Strategic Positioning: Zevra focuses on broadening market access through geographic expansion and advancing key milestones, with its lead product already marketed in the U.S. for Niemann-Pick disease type C, demonstrating a strong foundation in rare disease treatment.
- Commitment to Long-Term Value: The company's vision is realized through disciplined execution of its strategic plan, emphasizing core values such as patient centricity, integrity, accountability, innovation, and courage, which drive the creation of long-term value.
See More
Zevra Therapeutics Reports Q1 2026 Earnings with Strong Growth Indicators
- Significant Revenue Growth: Zevra Therapeutics reported net revenue of $36.2 million in Q1 2026, with $24.6 million from MIPLYFFA sales in the U.S., indicating strong performance in the rare disease market and potential for increased market share moving forward.
- Asset Optimization and Debt Clearance: The company divested its SDX portfolio to Commave Therapeutics for $50 million and successfully retired its debt early, marking Zevra as debt-free, which enhances financial flexibility for future strategic investments.
- Expanded Patient Access Program: As of Q1 2026, Zevra's global Expanded Access Program (EAP) has enrolled 122 patients, up from 113 at the end of 2025, indicating positive progress in improving patient treatment accessibility.
- Diversified Clinical Development Pathways: Zevra is actively preparing for follow-up meetings with the FDA to accelerate clinical development and plans to boost MIPLYFFA enrollment through multiple pathways, demonstrating the company's responsiveness to market demands and adaptability.
See More
